C R Bard Inc  

(Public, NYSE:BCR)   Watch this stock  
Find more results for BCR
-0.31 (-0.17%)
Oct 9 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 185.02 - 187.96
52 week 144.39 - 202.47
Open 186.37
Vol / Avg. 674,338.00/624,128.00
Mkt cap 13.88B
P/E 41.58
Div/yield 0.24/0.51
EPS 4.49
Shares 74.20M
Beta 0.76
Inst. own 90%
Oct 22, 2015
Q3 2015 C R Bard Inc Earnings Call - 5:00PM EDT - Add to calendar
Oct 22, 2015
Q3 2015 C R Bard Inc Earnings Release - 4:00PM EDT - Add to calendar
Sep 17, 2015
C R Bard Inc at Morgan Stanley Healthcare Conference
Jul 23, 2015
Q2 2015 C R Bard Inc Earnings Call - Webcast
Jul 23, 2015
Q2 2015 C R Bard Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -6.36% 8.86%
Operating margin 8.27% 14.54%
EBITD margin - 28.88%
Return on average assets -4.38% 5.81%
Return on average equity -12.88% 14.88%
Employees 13,900 -
CDP Score - -


730 Central Ave
United States - Map
+1-908-2778000 (Phone)
+1-908-2778412 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Company's vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.

Officers and directors

Timothy M. Ring Chairman of the Board, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John H. Weiland President, Chief Operating Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jim C. Beasley Group President
Age: 51
Bio & Compensation  - Reuters
Timothy P. Collins Group President
Age: 54
Bio & Compensation  - Reuters
Christopher S. Holland Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Samrat S. Khichi Senior Vice President, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
John A. DeFord Ph.D. Senior Vice President - Science, Technology and Clinical Affairs
Age: 53
Bio & Compensation  - Reuters
Frank Lupisella Jr. Vice President, Controller
Age: 54
Bio & Compensation  - Reuters
Sharon M. Alterio Group Vice President
Age: 52
Bio & Compensation  - Reuters
Patricia G. Christian Vice President - Quality, Regulatory and Medical Affairs
Age: 54
Bio & Compensation  - Reuters